Connect with us

Business

Morison commences local production of three high-in-demand medicines

Published

on

Morison Ltd., a pioneer in pharmaceutical manufacturing in Sri Lanka (formerly known as J.L. Morison’s Son & Jones (Ceylon) PLC), commenced manufacturing of Bisoprolol tablets B.P. 5mg 250s, Ros-10 (Rosuvastatin tablets I.P. 10mg 30s blister), and ChlorMor (Chlorphenamine tablets B.P. 4mg 100s blister) recently. This marks a milestone in the local pharmaceutical industry, as these high-in-demand medicines are now more affordable and accessible to our people, the supply of which does not have to depend on imports.

For the first time in Sri Lanka, Bisoprolol 5 mg tablets are now being manufactured locally by Morison and supplied to the Medical Supplies Division for the use in government hospitals. Used as a treatment for high blood pressure and other cardiovascular conditions, the annual requirement of Bisoprolol in the government sector is around 40 million tablets, which was being imported to date. By producing the same locally, Morison is able to make a significant forex saving for the national economy during these unprecedented times. Plans are underway to make Bisoprolol B.P. 2.5mg and 5 mg available in all leading pharmacies as a branded medication in due course, to enable purchasing through a valid prescription.

The second new product launched, Ros-10 (Rosuvastatin tablets I.P. 10mg 30s blister) is used to treat high blood cholesterol, a risk factor for cardiovascular disease. Morison launched Ros-10 at approximately half of the current weighted average market price, offering significant savings to Sri Lankans. The third latest addition to the Morison portfolio, ChlorMor (Chlorphenamine tablets B.P. 4mg 100s blister) is an oral antihistamine that helps to relieve symptoms of allergies. This too was launched at a price less than the prevailing similar products in the market.

Dinesh Athapaththu, Managing Director of Morison Limited, commented on the commencement of production of these pharmaceuticals saying, “This indeed is a key milestone for Morison as well as the pharmaceutical manufacturing industry in the country. Our purpose is to “Make Premium Healthcare Affordable”, and this is what we aim at achieving as we supply to the local demand for a lesser price, while maintaining the highest standards of quality. We commenced operations of our latest state-of-the-art manufacturing and research facility in Homagama in May this year, which is the largest investment to date in the pharmaceutical manufacturing industry in Sri Lanka. This will be a great boost for the pharmaceutical supply of the country during this crucial hour. As a subsidiary of the Hemas Group, Morison continues to receive the best of technology and knowledge investment in our journey.”

Being the first and largest general oral solid dosage (OSD) and oral liquid dosage (OLD) manufacturing facility in compliance with WHO GMP and EU GMP infrastructure and quality management systems in Sri Lanka, the Morison’s second manufacturing facility in Homagama, has the inbuilt capacity to produce 5 Bn tablets and 2 Mn litres of liquids per annum, which is equivalent to 40% of the national annual general OSD demand in Sri Lanka.

Prior to introducing Ros-10, Bisoprolol and ChlorMor, Morison launched the first ever locally manufactured SGLT2 molecule (Sodium-glucose cotransporter-2), Empagliflozin tablets 10mg and 25mg in 2021. An oral medication to treat Type 2 Diabetes, this was launched at approximately 50% price advantage from the market. The launch of the three new products is yet another progressive step of Morison, towards being a beacon of hope to Sri Lankans by “Making Premium Healthcare Affordable” in this critical juncture.



Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

CEB successor company breaks into top three in competitive BESS tender

Published

on

Snr. Eng. Pubudhu Niroshan: ‘Boon to consumers’

By Ifham Nizam

National Transmission Network Service Provider (Pvt) Ltd. (NTNSP), has secured third place in Sri Lanka’s fiercely contested 160 MW/640 MWh Battery Energy Storage System (BESS) tender, beating a number of established private-sector energy players in a major competitive procurement exercise just six months after the restructuring of the Ceylon Electricity Board (CEB).

The result marks a significant early indication that a newly restructured CEB successor company can compete on a commercial footing with established players in the rapidly expanding energy market, Senior Engineer Pubudhu Niroshan told The Island Financial Review.

More significantly, Niroshan said NTNSP’s entry into the tender helped intensify competition and contributed to a roughly 10% reduction in the lowest bid compared with the previous 160 MW/640 MWh BESS procurement, potentially delivering a more favourable outcome for electricity consumers.

“Entering such a highly competitive bidding process within just six months of restructuring and emerging third is by no means an easy task, Niroshan said.

He said the achievement had to be viewed in the context of the calibre and number of competitors involved in the process, adding that NTNSP had demonstrated that a successor company emerging from the CEB restructuring could step into a competitive commercial environment and hold its own against established businesses.

The significance of NTNSP’s participation, however, extended beyond its third-place ranking.

According to Niroshan, the company’s decision to enter the BESS procurement created an additional layer of competition, forcing other bidders to sharpen their commercial offers.

‘The first and second-ranked bidders had NTNSP as another competitor. That itself created additional competitive pressure, he said.

The BESS procurement involved a total capacity of 160 MW/640 MWh, with the programme divided into individual projects.

The procurement was designed to bring private and other eligible project proponents into the development and operation of battery storage facilities, providing an important mechanism for integrating renewable energy and strengthening the electricity system.

The outcome, he said, was particularly important for electricity consumers because greater competition in procurement could ultimately translate into lower costs for the power system.

‘Once you have several serious players competing, offering a fair and competitive price becomes essential. That is ultimately good for the consumer, he said.

Niroshan also referred to concerns previously raised by NTNSP before the Public Utilities Commission of Sri Lanka (PUCSL) regarding prices submitted for BESS projects under the Feed-in Tariff (FiT) mechanism.

He said subsequent market developments had provided support for the view that some of the prices submitted under the FiT mechanism were comparatively high.

For Niroshan, the experience also demonstrated why competition must remain at the heart of the restructuring of the electricity sector.

Continue Reading

Business

Hundred farming elders witness Sacred Dalada Perahera

Published

on

Serendib Flour Mills continued its longstanding commitment to rural communities through the fifth edition of Serendib Uththama Dalada, more than 100 elderly mothers and fathers from remote farming communities to experience the sacred Sri Dalada Perahera in Kandy.

Held on 26 August 2026, the initiative brought together elderly parents from Mahalakotuwa, Elahera and Attanakadawala, many of whom have spent a lifetime engaged in agriculture and contributing towards sustaining communities across the country. For these elders, the initiative offered an opportunity to undertake a deeply meaningful spiritual journey and witness one of Sri Lanka’s most revered religious and cultural traditions.

Conducted under the campaign thought, “Nourishing the hearts of elderly parents with spiritual merits, who once nourished a generation,” Serendib Uththama Dalada recognises the lifelong contribution and sacrifices of farming mothers and fathers while creating an experience that may otherwise remain beyond their reach.

Serendib Flour Mills facilitated the entire journey, providing safe and comfortable return transportation to Kandy aboard three dedicated buses. Special arrangements were also made to enable the participants to worship at the Sri Dalada Maligawa, followed by reserved seating at a specially erected VIP stand, allowing them to comfortably witness the grandeur of the Dalada Perahera.

Continue Reading

Business

Siyapatha Finance records ‘exceptional financial performance for 1H2026’

Published

on

Sumith Cumaranatunga, Chairman / Mathisha Hewavitharana, CEO

Siyapatha Finance PLC, the largest fully-owned finance company of the Sampath Bank Group, delivered an exceptional financial performance for the six months ended 30 June 2026, reflecting the Company’s continued strategic growth initiatives, resilient asset quality, and unwavering commitment to sustainable value creation.

The Company recorded a profit after tax (PAT) of Rs. 1,007 million, a robust 43 percent increase from Rs. 706 million in the corresponding period of 2025, while profit before taxes (PBT) grew 38 percent to Rs. 2,334 million from Rs. 1,689 million, demonstrating sustained market and customer confidence in the Company’s core operations.

“Our performance in the first half of 2026 is a clear reflection of Siyapatha Finance’s strategic foresight and our unwavering commitment to sustainable growth,” said Siyapatha Finance Chief Executive Officer Mathisha Hewawitharana. “Surpassing the Rs. 104 billion mark in total assets while significantly improving our asset quality underscores the strength of our core operations and the deep trust our customers place in us. As we navigate the evolving macroeconomic landscape, we remain focused on prudent risk management and delivering enhanced value to our stakeholders.”

The Company’s core business operations continued to yield strong returns, with total interest income growing to Rs. 7,719 million from Rs. 5,272 million a year earlier, driving net interest income up to Rs. 3,487 million from Rs. 2,629 million, signifying the Company’s efficient management of assets and liabilities. Other income strengthened to Rs. 1,054 million from Rs. 826 million, reinforcing the effectiveness of the Company’s revenue diversification strategy. The cost-to-income ratio improved to 49 percent from 54 percent, a testament to the Company’s continued focus on operational efficiency and process optimization.

Asset quality strengthened markedly during the period, underscoring the success of Siyapatha Finance’s prudent credit risk management and proactive recovery initiatives. The gross stage 3 loans ratio improved to 4 percent from 8 percent a year earlier, while the net stage 3 loans ratio declined to 2 percent from 3 percent.

Continue Reading

Trending